tradingkey.logo
tradingkey.logo
Search

SIGA Technologies Inc

SIGA
Add to Watchlist
4.170USD
-0.090-2.11%
Close 05/15, 16:00ETQuotes delayed by 15 min
299.09MMarket Cap
14.74P/E TTM

SIGA Technologies Inc

4.170
-0.090-2.11%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of SIGA Technologies Inc

Currency: USD Updated: 2026-05-15

Key Insights

SIGA Technologies Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 108 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SIGA Technologies Inc's Score

Industry at a Glance

Industry Ranking
108 / 155
Overall Ranking
359 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

SIGA Technologies Inc Highlights

StrengthsRisks
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company is focused on the development of medicines to treat and prevent infectious diseases. Its flagship product, TPOXX (tecovirimat), is an antiviral medicine approved in the United States and Canada for the treatment of smallpox and authorized in Europe, the United Kingdom, and Japan for the treatment of smallpox, monkeypox (mpox), cowpox, and vaccinia complications. TPOXX specifically inhibits the activity of a protein called VP37, found on the surface of all orthopoxviruses. This prevents the virus from leaving infected cells, slowing the spread of the infection and limiting it to a point where the immune system can clear the virus. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.
Growing
The company is in a growing phase, with the latest annual income totaling USD 94.57M.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 72.80%.
Overvalued
The company’s latest PE is 14.74, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.67M shares, increasing 0.80% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 689.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.24.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of SIGA Technologies Inc is 7.78, ranking 86 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 6.24M, representing a year-over-year decrease of 11.34%, while its net profit experienced a year-over-year decrease of 746.17%.

Score

Industry at a Glance

Previous score
7.78
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

9.66

Operational Efficiency

10.00

Growth Potential

3.84

Shareholder Returns

5.39

SIGA Technologies Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of SIGA Technologies Inc is 5.26, ranking 147 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 14.74, which is 17.80% below the recent high of 17.36 and 612.87% above the recent low of -75.58.

Score

Industry at a Glance

Previous score
5.26
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 108/155
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

No earnings forecast score is currently available for SIGA Technologies Inc. The Pharmaceuticals industry's average is 7.89.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of SIGA Technologies Inc is 6.70, ranking 87 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.70 and the support level at 3.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.48
Change
0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.034
Sell
RSI(14)
30.569
Neutral
STOCH(KDJ)(9,3,3)
9.864
Oversold
ATR(14)
0.179
High Vlolatility
CCI(14)
-179.084
Sell
Williams %R
90.909
Oversold
TRIX(12,20)
-0.270
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
4.348
Sell
MA10
4.524
Sell
MA20
4.537
Sell
MA50
4.824
Sell
MA100
5.707
Sell
MA200
6.752
Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of SIGA Technologies Inc is 5.00, ranking 73 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 55.31%, representing a quarter-over-quarter increase of 10.57%. The largest institutional shareholder is HOTCHKIS & WILEY, holding a total of 819.45K shares, representing 1.14% of shares outstanding, with 74.16% decrease in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
MacAndrews & Forbes Holdings, Inc.
24.16M
--
Lewis (John Latane IV)
5.27M
--
BlackRock Institutional Trust Company, N.A.
2.79M
+0.86%
Dimensional Fund Advisors, L.P.
2.54M
+4.29%
AltraVue Capital, LLC.
2.41M
-0.36%
American Century Investment Management, Inc.
1.17M
-5.45%
State Street Investment Management (US)
1.08M
+4.03%
Citadel Advisors LLC
1.04M
-7.29%
Arrowstreet Capital, Limited Partnership
1.03M
+22.81%
1
2

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SIGA Technologies Inc is 5.23, ranking 72 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
5.23
Change
0
Beta vs S&P 500 index
0.89
VaR
+5.30%
240-Day Maximum Drawdown
+56.01%
240-Day Volatility
+46.44%

Return

Best Daily Return
60 days
+6.85%
120 days
+6.85%
5 years
+43.35%
Worst Daily Return
60 days
-12.21%
120 days
-12.21%
5 years
-28.30%
Sharpe Ratio
60 days
-3.71
120 days
-1.54
5 years
+0.40

Risk Assessment

Maximum Drawdown
240 days
+56.01%
3 years
+61.53%
5 years
+82.12%
Return-to-Drawdown Ratio
240 days
-0.56
3 years
-0.01
5 years
-0.03
Skewness
240 days
-0.44
3 years
-0.29
5 years
+1.55

Volatility

Realised Volatility
240 days
+46.44%
5 years
+71.22%
Standardised True Range
240 days
+6.45%
5 years
+8.77%
Downside Risk-Adjusted Return
120 days
-192.21%
240 days
-192.21%
Maximum Daily Upside Volatility
60 days
+37.39%
Maximum Daily Downside Volatility
60 days
+47.37%

Liquidity

Average Turnover Rate
60 days
+0.95%
120 days
+0.72%
5 years
--
Turnover Deviation
20 days
-21.88%
60 days
+10.67%
120 days
-16.27%

Peer Comparison

Pharmaceuticals
SIGA Technologies Inc
SIGA Technologies Inc
SIGA
5.10 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI